Investors are preparing for a critical financial update from Healwell AI Inc. The Canadian healthcare artificial intelligence company is scheduled to release its complete fiscal 2025 results on March 19, 2026. This report will mark a significant milestone, as it will be the first to fully incorporate the financial impact of the Orion Health acquisition.
A Strategic Shift in Profile
The company’s structural transformation, driven by the Orion Health deal which closed on April 1, 2025, is now central to its story. To sharpen its focus, Healwell divested two non-core business units and contributed two others to a clinical research joint venture. This strategic streamlining aims to position Healwell as a dedicated enterprise software and AI business.
Evidence of this shift was already apparent in the Q3 2025 figures. Revenue from continuing operations surged to $30.4 million for the quarter, representing a 354% year-over-year increase. A particularly strong performance was seen in subscription and maintenance revenue, which jumped to $21.0 million—a gain of 535%. Notably, the company achieved a positive adjusted EBITDA for two consecutive quarters, a first in recent periods. Despite this, the IFRS net loss from continuing operations remained substantial at $16.0 million. The market will now scrutinize whether this operational trend continued into the final quarter of the year.
Clinical Validation and Market Growth
Ahead of the earnings release, Healwell has continued to build the scientific credibility of its DARWEN AI platform. New studies have been accepted for presentation at major international medical conferences, including the annual congress of the European Crohn’s and Colitis Organisation, with publication in the Journal of Crohn’s and Colitis. The platform’s research foundation now encompasses 47 peer-reviewed publications and real-world evidence studies.
Should investors sell immediately? Or is it worth buying Healwell AI?
On the commercial front, the company recently secured a multi-million-dollar Health Information Exchange (HIE) software contract in the United States. Furthermore, in late February, it announced its first AI deployment in the Middle East. The existing Orion Health infrastructure in the region already connects over 3,000 facilities in the United Arab Emirates and more than 5,000 providers in Saudi Arabia, providing a substantial foundation for expansion.
The Stakes for the Upcoming Report
Healwell’s share price has recovered significantly from its February lows, currently trading approximately 43% higher than its level one month ago. However, the equity remains nearly 50% below its 52-week high from March 2025, underscoring the ground the company still needs to regain in investor confidence.
The annual results on March 19 will be pivotal in demonstrating whether the positive adjusted EBITDA trend from Q3 has been sustained. Investors will also be looking for confirmation that the high revenue growth rate associated with the Orion integration can be maintained. Following the release, a conference call with CEO James Lee and CFO Anthony Lam is scheduled for March 20. Additionally, President Alexander Dobranowski is set to participate in the ROTH investor panel on healthcare AI on March 23.
Ad
Healwell AI Stock: Buy or Sell?! New Healwell AI Analysis from March 17 delivers the answer:
The latest Healwell AI figures speak for themselves: Urgent action needed for Healwell AI investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 17.
Healwell AI: Buy or sell? Read more here...
